Drug intelligence / Profile preview

Ag-Phage P

Development stage: Preclinical
Lead developer: iNtRON Biotechnology
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Ag-Phage P is a preclinical bacteriophage-based vaccine candidate developed by iNtRON Biotechnology for the prevention of avian influenza. Utilizing the proprietary IMPA™ (Immune-Modulating Phage Application) platform, the vaccine is engineered to display avian influenza antigens on the surface of bacteriophage particles. This approach leverages the inherent immunogenicity of the phage to act as both a delivery vehicle and an adjuvant, stimulating a robust immune response against the targeted viral antigens. The IMPA™ platform is designed to enhance antigen presentation and induce both humoral and cellular immunity without the need for traditional chemical adjuvants.

Other names: Ag-Phage P (Avian Influenza)IMPA-Avian Influenza vaccine

Beyond the preview

Go deeper on Ag-Phage P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ag-Phage P.

Explore the full profile